Skip main navigation

Hurry, only 2 days left to get one year of Unlimited learning for £249.99 £174.99. New subscribers only. T&Cs apply

Find out more

Case study: PCSK9 cholesterol-lowing drugs

Case study: PCSK9 cholesterol-lowing drugs

LDL-cholesterol is known as “bad cholesterol” because at high levels it can cause plaque to accumulate on your artery walls and increase the risk of heart attack or stroke.

Statins (such as atorvastatin, fluvastatin, lovastatin and et al.) are one of the most common pharmaceutical methods used to lower cholesterol but some patients do not have a response to statin treatments. Therefore, in 2015, PCSK9 inhibitors were approved by the FDA as new treatment to reduce cholesterol levels. The inhibitors target a protein in the liver known as proprotein convertase subtilisin/kexin type 9 (PCSK9).

This video will introduce the history of the development of PCSK9 inhibitors.

This article is from the free online

Introduction to Translational Research: Connecting Scientists and Medical Doctors

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now